Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513132 | 0.99 | L3MBTL3 (0.57) | L3MBTL3L3MBTL1SMN1; SMN2HTTLMNA | |
| SCHEMBL3511838 | 0.96 | L3MBTL1 (0.54) | L3MBTL3L3MBTL1SMN1; SMN2HTTLMNA | |
| SCHEMBL3512031 | 0.89 | GAA (0.64) | L3MBTL1SMN1; SMN2HTTLMNAALDH1A1 | |
| SCHEMBL28784217 | 0.89 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1SMN1; SMN2HTTLMNA | |
| SCHEMBL28811177 | 0.87 | L3MBTL3 (0.55) | L3MBTL3L3MBTL1SMN1; SMN2HTTLMNA | |
| SCHEMBL20456915 | 0.87 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1SMN1; SMN2HTTLMNA | |
| SCHEMBL1354618 | 0.83 | L3MBTL3 (0.62) | L3MBTL3L3MBTL1SMN1; SMN2HTTLMNA | |
| SCHEMBL3512823 | 0.80 | CASP6 (0.55) | LMNAGAAPOLBMAPTMEN1 | |
| SCHEMBL3639905 | 0.80 | L3MBTL1 (0.65) | L3MBTL3L3MBTL1SMN1; SMN2HTTLMNA | |
| SCHEMBL12980667 | 0.80 | MAPT (0.46) | L3MBTL1SMN1; SMN2HTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-05-12 | — | — | US | disclosed |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-12-03 | — | — | US | disclosed |
| US-20190241546-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-08-08 | — | — | US | disclosed |
| US-10081622-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-09-25 | — | — | US | disclosed |
| US-20170158677-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-08 | — | — | US | disclosed |
| US-9616059-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-04-11 | — | — | US | disclosed |
| EP-2176231-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-10-19 | — | — | EP | disclosed |
| US-20160095856-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-07 | — | — | US | disclosed |
| US-9255087-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-02-09 | — | — | US | disclosed |
| US-9102662-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-08-11 | — | — | US | disclosed |
| US-20150065520-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-05 | — | — | US | disclosed |
| US-20150057291-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20150057292-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20140228351-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-14 | — | — | US | disclosed |
| US-8673893-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-18 | — | — | US | disclosed |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-8299057-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-30 | — | — | US | disclosed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | disclosed |
| EP-2176231-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081622-B2 | Substituted indazole derivatives active as kinase inhibitors | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | L3MBTL3 2256/4885L3MBTL1 2408/4885SMN1; SMN2 3441/4885 |
| US-20160095856-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20200377487-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20190241546-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | L3MBTL3 2256/4885L3MBTL1 2408/4885SMN1; SMN2 3441/4885 |
| US-20150065520-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20150057292-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20140228351-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20150057291-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
| US-20170158677-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | L3MBTL3 1401/4885L3MBTL1 1397/4885SMN1; SMN2 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.